Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Interval Exercise Training (IET) Is Feasible and May Improve Cardiorespiratory Performance Prior to Hematopoietic Cell Transplantation

Mathew Meeneghan, MD, Anna Snavely, PhD, Abbie Smith-Ryan, PhD, Claudio L Battaglini, PhD, Bryce B Reeve, PhD, Ethan Basch, MD MSc, Antonia Bennett, PhD, Charlotte Shatten, MA, Brett Phillips, BS, Jonathan Serody, MD, PhD, Don A. Gabriel, MD PhD, Katarzyna Joanna Jamieson, MD, James Coghill, MD, Paul M. Armistead, MD PhD, Thomas C. Shea, MD, William A. Wood, MD MPH

Blood (2014) 124 (21): 2611.

https://doi.org/10.1182/blood.V124.21.2611.2611

Published: 2014

Journal Articles

Symptomatic Improvement Following Intravesicular Cidofovir for the Management of BK Virus Associated Cystitis.

Larry W. Buie, PharmD, Kamakshi V. Rao, PharmD, Stacy Epstein, PharmD, Thomas C. Shea, MD, Terrence Comeau, MD, Don A. Gabriel, MD PhD, Robert Irons, PA, Barbara Eron, RN, Jonathan Serody, MD PhD

Blood (2007) 110 (11): 3007.

https://doi.org/10.1182/blood.V110.11.3007.3007

Published: 2007

Journal Articles

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

Thomas Shea, MD, Jonathan Serody, MD, PhD, Don Gabriel, MD, PhD, Terrance Comeau, MD, Anastasia Ivanova, PhD, Dominic Moore, PhD, Robert Irons, PA, Whitley Julia, BS, Sharf Andrew, RN, Cherie Dunphy, MD, Brecher Mark, MD

Blood (2007) 110 (11): 4940.

https://doi.org/10.1182/blood.V110.11.4940.4940

Published: 2007

Journal Articles

Mitoxantrone and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplant for Multiple Myeloma.

Anne W. Beaven, MD, Terrance Comeau, MD, Andrew Sharf, RN, Dominic T. Moore, MPH, Jonathan Serody, MD, PhD, Thomas C. Shea, MD, Don A. Gabriel, MD, PhD

Blood (2006) 108 (11): 2945.

https://doi.org/10.1182/blood.V108.11.2945.2945

Published: 2006

Journal Articles

Long Term Effects on GVHD and Survival Following the Use of G-CSF Stimulated Bone Marrow Versus G-CSF Mobilized Peripheral Blood Stem Cells in HLA Matched Sibling Transplant.

Anne W. Beaven, MD, Thomas C. Shea, MD, Don A. Gabriel, MD, PhD, Terrance Comeau, MD, Robert Irons, PA, Dominic T. Moore, MS, MPH, Li Lin, MS, Andrew Sharf, RN, Carol Krasnov, Mark E. Brecher, MD, Jonathan Serody, MD, PhD

Blood (2005) 106 (11): 5385.

https://doi.org/10.1182/blood.V106.11.5385.5385

Published: 2005

Journal Articles

High Relapse Rate Following Alemtuzamab Use in Allogeneic Transplants for Myeloid Hematologic Malignancies.

Thomas C. Shea, MD, Jonathan Serody, MD, PhD, Don Gabriel, MD, PhD, Terrance Comeau, MD, Donald Harvey, PharmD, Robert Irons, PA, David Morris, MD, Andrew Sharf, RN, Carol Krasnov, Cherie Dunphy, MD, Nicholas Banderenko, MD, Mark Brecher, MD

Blood (2004) 104 (11): 1826.

https://doi.org/10.1182/blood.V104.11.1826.1826

Published: 2004

Journal Articles

Visualizing Allogeneic Bone Marrow (BM) Graft Rejection.

Patricia Taylor, DVM, Angela Panoskaltsis-Mortari, PhD, Randolph Noelle, PhD, Alexander Rudensky, PhD, Jonathan Serody, MD, PhD, Bruce Blazar, MD

Blood (2004) 104 (11): 43.

https://doi.org/10.1182/blood.V104.11.43.43

Published: 2004

Journal Articles

The ICOS:ICOSL Costimulatory Pathway Plays an Important Role in GVHD and Bone Marrow (BM) Graft Rejection.

Patricia Taylor, DVM, Angela Panoskaltsis-Mortari, PhD, Gordon Freeman, PhD, Arlene Sharpe, MD, PhD, Randolph Noelle, PhD, Alexander Rudensky, PhD, Tak Mak, MD, PhD, Jonathan Serody, MD, PhD, Bruce Blazar, MD

Blood (2004) 104 (11): 591.

https://doi.org/10.1182/blood.V104.11.591.591

Published: 2004

NARROW

Interval Exercise Training (IET) Is Feasible and May Improve Cardiorespiratory Performance Prior to Hematopoietic Cell Transplantation

Symptomatic Improvement Following Intravesicular Cidofovir for the Management of BK Virus Associated Cystitis.

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

Mitoxantrone and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplant for Multiple Myeloma.

Long Term Effects on GVHD and Survival Following the Use of G-CSF Stimulated Bone Marrow Versus G-CSF Mobilized Peripheral Blood Stem Cells in HLA Matched Sibling Transplant.

High Relapse Rate Following Alemtuzamab Use in Allogeneic Transplants for Myeloid Hematologic Malignancies.

Visualizing Allogeneic Bone Marrow (BM) Graft Rejection.

The ICOS:ICOSL Costimulatory Pathway Plays an Important Role in GVHD and Bone Marrow (BM) Graft Rejection.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only